Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
Posted On: 03/10/2015 9:39:21 AM
Post# of 30070
Avatar
Posted By: Mauibound
"Dyskinesia impacts quality of life of people with Parkinson's disease, and is therefore a top priority for the Foundation," commented Maurizio Facheris, M.D., M.Sc., Associate Director of research programs at The Michael J. Fox Foundation. "We are glad to see this project moving further through clinical testing and closer to patients' hands."
http://ir.amarantus.com/company-news/detail/1...dyskinesia

The Research Programs team, made up of PhD and MD neuroscientists paired with business-trained project managers, manages the Foundation’s research portfolio of approximately 250 active grants. This team works closely with Foundation peer reviewers to make funding decisions, direct research goals and troubleshoot issues as they arise.

Maurizio Facheris, MD, MSc
Senior Associate Director
Research Programs
https://www.michaeljfox.org/foundation/leader...h-programs

Cheers













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site